<DOC>
	<DOCNO>NCT00066599</DOCNO>
	<brief_summary>RATIONALE : Voriconazole may effective prevent systemic fungal infection follow chemotherapy . PURPOSE : Phase II trial study effectiveness voriconazole prevent systemic fungal infection child neutropenia receive chemotherapy leukemia , lymphoma , aplastic anemia preparation bone marrow stem cell transplantation .</brief_summary>
	<brief_title>Voriconazole Preventing Fungal Infections Children With Neutropenia After Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine pharmacokinetics voriconazole administer IV orally prevention systemic fungal infection pediatric patient neutropenia chemotherapy . - Determine safety tolerability drug patient . OUTLINE : This pilot , open-label , multicenter study . Patients stratify accord age ( 2 5 v 6 11 ) . Within 48 hour completion chemotherapy , patient begin prophylactic therapy : - Cohort 1 ( first 18 patient , 9 per stratum ) : Patients receive voriconazole IV 80-160 minute twice daily day 1-8 oral voriconazole* twice daily begin day 9 . Depending result interim pharmacokinetic analysis , last 18 patient enter study receive 1 follow regimen : - Cohort 2A : Patients receive voriconazole cohort 1 high dose . - Cohort 2B : Patients receive voriconazole IV 80-160 minute twice daily day 1-4 oral voriconazole* twice daily begin day 5 . NOTE : *Patients unable tolerate oral medication may continue receive IV medication day 20 . In cohort , treatment continue blood count recover day 30 absence unacceptable toxicity progression infection . Patients follow 30 day 12 month . PROJECTED ACCRUAL : A total 49 patient ( approximately 24 per stratum ) accrue study within 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Expected develop neutropenia ( absolute neutrophil count le 500/mm^3 ) last 10 day chemotherapy 1 follow condition : Leukemia Lymphoma Aplastic anemia Preparation bone marrow stem cell transplantation Requiring treatment prevention systemic fungal infection PATIENT CHARACTERISTICS : Age 2 11 Performance status Not specify Life expectancy More 3 month Hematopoietic See Disease Characteristics Hepatic AST ALT great 5 time upper limit normal ( ULN ) Bilirubin great 5 time ULN Renal Creatinine clearance least 30 mL/min Cardiovascular No cardiac arrhythmia Other Not pregnant nursing Negative pregnancy test No severe hypokalemia ( potassium le 3.2 mmol/L ) No prior hypersensitivity severe intolerance azole antifungal agent No concurrent condition would preclude study therapy PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 24 hour since prior use following : Terfenadine Pimozide Quinidine Astemizole Cisapride Omeprazole More 14 day since prior use following : Rifampin Rifabutin Carbamazepine Phenytoin Nevirapine Longacting barbiturates No prior sirolimus No prior enrollment study No concurrent use follow : Terfenadine Pimozide Quinidine Astemizole Cisapride Omeprazole No concurrent investigational drug except follow : Drugs use treatment cancer Antiretroviral agent Drugs use treatment AIDSdefining opportunistic infection No concurrent enrollment investigational anticancer drug trial exclude use investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>recurrent childhood lymphoblastic lymphoma</keyword>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>recurrent childhood large cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>childhood acute myeloid leukemia remission</keyword>
	<keyword>recurrent childhood acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute myeloid leukemia myeloid malignancy</keyword>
	<keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
	<keyword>stage I childhood Hodgkin lymphoma</keyword>
	<keyword>stage II childhood Hodgkin lymphoma</keyword>
	<keyword>stage III childhood Hodgkin lymphoma</keyword>
	<keyword>stage IV childhood Hodgkin lymphoma</keyword>
	<keyword>childhood acute promyelocytic leukemia ( M3 )</keyword>
	<keyword>previously treat childhood rhabdomyosarcoma</keyword>
	<keyword>recurrent Wilms tumor childhood kidney tumor</keyword>
	<keyword>recurrent childhood rhabdomyosarcoma</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>meningeal chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>intraocular lymphoma</keyword>
	<keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>acute undifferentiated leukemia</keyword>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>disseminate neuroblastoma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>